Vivus' Post-Panel Stock Surge Prompts Hefty Public Offering
By Jennifer Boggs
Thursday, March 1, 2012
Given the 125 percent stock surge after last week's positive FDA panel review for obesity candidate Qnexa (phentermine/topiramate), Vivus Inc.'s plan for a public offering comes as little surprise.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.